Clinical Trial Update: Bioequivalence of Two Mixtard® 30 Formulations in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study indicating bioequivalence between two Mixtard 30 insulin formulations in healthy subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Mixtard 30 (insulin isophane human)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Healthy | Phase 1 | Status: COMPLETED